Monday, 11 May 2026
  
Login

Australia's most trusted
source of pharma news

Monday, 11 May 2026
News

Three companies add new drugs

Posted 11 May 2026 AM

The TGA has approved three new products - Chiesi’s Filsuvez, Seqirus’ Ryaltris Allergy, and Specialised Therapeutics’ Niktimvo – plus a subcutaneous version of AstraZeneca’s Saphnelo.

Filsuvez is a topical gel indicated for the treatment of partial thickness wounds associated with dystrophic and junctional epidermolysis bullosa in patients six months and older while Ryaltris Allergy is indicated for the treatment of symptoms associated with allergic rhinitis and rhinoconjunctivitis for up to six months in adults and children 12 years of age and over.

To see the whole article, please login

Popular

$135M market under threat
Industry's 'Most Influential' named
Aussie class action targets pharma
PBAC July Agenda blows out to 58
Latest Jobs
MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2026 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home